127 results
424B3
PRTG
Portage Biotech Inc
6 Mar 24
Prospectus supplement
9:36pm
PORT - 7: Highly Selective and Potent A2B Adenosine Receptor Antagonist High potency and selectivity may provide important safety and efficacy advantages … , Renal Cell Cancer with high A2A expression PORT - 6 1a: MONOTHERAPY (Safety) Phase 1a Starting Dose (200 mg QD) (n=9 - 12) PORT - 7 100 mg 800 mg
6-K
EX-99.1
PRTG
Portage Biotech Inc
6 Mar 24
Current report (foreign)
9:11pm
Antagonist High potency and selectivity may provide important safety and efficacy advantages Activity in 4T1, CT26, and other disease models (asthma … : MONOTHERAPY (Safety) Phase 1a Starting Dose (200 mg QD) (n=9 - 12) PORT - 7 100 mg 800 mg Recommended P2 Dose Recommended P2 Dose PORT - 6 + PORT - 7 PORT
6-K
EX-99.1
PRTG
Portage Biotech Inc
28 Feb 24
Company focused on adenosine platform clinical development
6:42pm
(pembrolizumab), Merck’s anti-PD-1 therapy,” continued Dr. Walters.
Pipeline Updates
Following the Trial Safety Committee recommendation, the Company
424B3
PRTG
Portage Biotech Inc
28 Feb 24
Prospectus supplement
5:19pm
-601 clinical trial to evaluate the activity and safety of PORT-6 and PORT-7 alone and in combination. This trial will adapt over time and also include … safety cohorts for these two agents with other immune activating agents including others from our internal pipeline. Depending on the data, it can
6-K
EX-99.2
PRTG
Portage Biotech Inc
28 Feb 24
Current report (foreign)
5:17pm
of action on different tumors.
We have designed the ADPORT-601 clinical trial to evaluate the activity and safety of PORT-6 and PORT-7 alone … and in combination. This trial will adapt over time and also include safety cohorts for these two agents with other immune activating agents including others
424B3
o5otjnbg5hbc5tzohbqf
18 Jan 24
Prospectus supplement
5:41pm
6-K
EX-99.1
ks0vaaini9 ko
18 Jan 24
Current report (foreign)
5:09pm
424B3
bjaxw3m0aimw2l atpyx
4 Jan 24
Prospectus supplement
5:49pm
6-K
EX-99.1
y99pi98lndue0
4 Jan 24
Current report (foreign)
8:10am
424B3
0e7sp6akk
28 Nov 23
Prospectus supplement
4:03pm
6-K
EX-99.2
yng0 5z8p
28 Nov 23
Current report (foreign)
4:01pm
424B3
aw15ap 0s3p8gto
14 Nov 23
Prospectus supplement
6:00am
6-K
EX-99.1
x91eqo5
13 Nov 23
Current report (foreign)
6:10am
6-K
EX-10.1
z877o5qj6
3 Oct 23
Current report (foreign)
4:05pm
424B5
1auuo7d
2 Oct 23
Prospectus supplement for primary offering
6:01pm
6-K
EX-99.1
u5iqe8o77
8 Sep 23
Current report (foreign)
4:01pm
6-K
EX-99.1
zra 32pnb
30 Aug 23
Current report (foreign)
8:00am
6-K
EX-99.2
1fewfj5kwunvvobv t72
29 Aug 23
Current report (foreign)
4:01pm
6-K
EX-99.1
k7ch1
14 Aug 23
Current report (foreign)
4:52pm
6-K
EX-99.1
lqepq
31 Jul 23
Current report (foreign)
6:10pm